{"id":1665,"date":"2021-02-08T12:02:40","date_gmt":"2021-02-08T20:02:40","guid":{"rendered":"http:\/\/mydiabeticsoul.com\/?p=1665"},"modified":"2021-02-08T12:02:40","modified_gmt":"2021-02-08T20:02:40","slug":"9-ooooh-regenerative-medicine","status":"publish","type":"post","link":"http:\/\/mydiabeticsoul.com\/?p=1665","title":{"rendered":"#9…Ooooh….”Regenerative Medicine”"},"content":{"rendered":"\n\n\n
\"\"<\/a><\/td>\n\n

Anticipating the Future of Regenerative Medicine: CIRM\u2019s Alpha Stem Cell Clinics\u00a0Network<\/a><\/h2>\n

by Yimy Villa<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n
\n
\"\"<\/a><\/figure>\n<\/div>\n

All this month we are using our blog and social media to highlight a new chapter in CIRM\u2019s life, thanks to the voters approving Proposition 14. We are looking back at what we have done since we were created in 2004, and also looking forward to the future. Today we take a deeper dive into CIRM\u2019s Alpha Stem Cell Clinics Network.\u00a0 The following is written by Dr. Geoff Lomax, Senior Officer of CIRM Therapeutics and Strategic Infrastructure.<\/em><\/p>\n

The year 2014 has been described as the regenerative medicine renaissance<\/a>: the European Union approved its first stem cell-based therapy and the FDA authorized ViaCyte\u2019s<\/a> CIRM funded clinical trial for diabetes. A path forward for stem cell treatments had emerged and there was a growing pipeline of products moving towards the clinic. At the time, many in the field came to recognize the need for clinical trial sites with the expertise to manage this growing pipeline. Anticipating this demand, CIRM\u2019s provided funding for a network of medical centers capable of supporting all aspect of regenerative medicine clinical trials. In 2015, the Alpha Stem Cell Clinics Network<\/a> was launched to for this purpose.<\/p>\n

The Alpha Clinics Network is comprised of leading California medical centers with specific expertise in delivering patient-centered stem cell and gene therapy treatments. UC San Diego, City of Hope, UC Irvine and UC Los Angeles were included in the initial launch, and UC San Francisco and UC Davis entered the network in 2017. Between 2015 and 2020 these sites supported 105 regenerative medicine clinical trials<\/a>. Twenty-three were CIRM-funded clinical trials<\/a> and the remaining 82 were sponsored by commercial companies or the Alpha Clinic site. These trials are addressing unmet medical needs for almost every disease where regenerative medicine is showing promise including blindness, blood disorders (e.g. sickle cell disease) cancer, diabetes, HIV\/AIDS, neurological diseases among others.<\/p>\n

As of spring of 2020 the network had inked over $57 million in contracts with commercial sponsors. High demand for Alpha Clinics reflects the valuable human and technical resources they provide clinical trial sponsors. These resources include:<\/p>\n